Cargando…

AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures

Can you imagine a disease in which intake of an excess amount of sugars or carbohydrates causes hyperammonemia? It is hard to imagine the intake causing hyperammonemia. AGC2 or citrin deficiency shows their symptoms following sugar/carbohydrates intake excess and this disease is now known as a pan-e...

Descripción completa

Detalles Bibliográficos
Autores principales: Saheki, Takeyori, Moriyama, Mitsuaki, Funahashi, Aki, Kuroda, Eishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465890/
https://www.ncbi.nlm.nih.gov/pubmed/32722104
http://dx.doi.org/10.3390/biom10081100
_version_ 1783577685931327488
author Saheki, Takeyori
Moriyama, Mitsuaki
Funahashi, Aki
Kuroda, Eishi
author_facet Saheki, Takeyori
Moriyama, Mitsuaki
Funahashi, Aki
Kuroda, Eishi
author_sort Saheki, Takeyori
collection PubMed
description Can you imagine a disease in which intake of an excess amount of sugars or carbohydrates causes hyperammonemia? It is hard to imagine the intake causing hyperammonemia. AGC2 or citrin deficiency shows their symptoms following sugar/carbohydrates intake excess and this disease is now known as a pan-ethnic disease. AGC2 (aspartate glutamate carrier 2) or citrin is a mitochondrial transporter which transports aspartate (Asp) from mitochondria to cytosol in exchange with glutamate (Glu) and H(+). Asp is originally supplied from mitochondria to cytosol where it is necessary for synthesis of proteins, nucleotides, and urea. In cytosol, Asp can be synthesized from oxaloacetate and Glu by cytosolic Asp aminotransferase, but oxaloacetate formation is limited by the amount of NAD(+). This means an increase in NADH causes suppression of Asp formation in the cytosol. Metabolism of carbohydrates and other substances which produce cytosolic NADH such as alcohol and glycerol suppress oxaloacetate formation. It is forced under citrin deficiency since citrin is a member of malate/Asp shuttle. In this review, we will describe history of identification of the SLC25A13 gene as the causative gene for adult-onset type II citrullinemia (CTLN2), a type of citrin deficiency, pathophysiology of citrin deficiency together with animal models and possible treatments for citrin deficiency newly developing.
format Online
Article
Text
id pubmed-7465890
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74658902020-09-04 AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures Saheki, Takeyori Moriyama, Mitsuaki Funahashi, Aki Kuroda, Eishi Biomolecules Review Can you imagine a disease in which intake of an excess amount of sugars or carbohydrates causes hyperammonemia? It is hard to imagine the intake causing hyperammonemia. AGC2 or citrin deficiency shows their symptoms following sugar/carbohydrates intake excess and this disease is now known as a pan-ethnic disease. AGC2 (aspartate glutamate carrier 2) or citrin is a mitochondrial transporter which transports aspartate (Asp) from mitochondria to cytosol in exchange with glutamate (Glu) and H(+). Asp is originally supplied from mitochondria to cytosol where it is necessary for synthesis of proteins, nucleotides, and urea. In cytosol, Asp can be synthesized from oxaloacetate and Glu by cytosolic Asp aminotransferase, but oxaloacetate formation is limited by the amount of NAD(+). This means an increase in NADH causes suppression of Asp formation in the cytosol. Metabolism of carbohydrates and other substances which produce cytosolic NADH such as alcohol and glycerol suppress oxaloacetate formation. It is forced under citrin deficiency since citrin is a member of malate/Asp shuttle. In this review, we will describe history of identification of the SLC25A13 gene as the causative gene for adult-onset type II citrullinemia (CTLN2), a type of citrin deficiency, pathophysiology of citrin deficiency together with animal models and possible treatments for citrin deficiency newly developing. MDPI 2020-07-24 /pmc/articles/PMC7465890/ /pubmed/32722104 http://dx.doi.org/10.3390/biom10081100 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Saheki, Takeyori
Moriyama, Mitsuaki
Funahashi, Aki
Kuroda, Eishi
AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures
title AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures
title_full AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures
title_fullStr AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures
title_full_unstemmed AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures
title_short AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures
title_sort agc2 (citrin) deficiency—from recognition of the disease till construction of therapeutic procedures
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465890/
https://www.ncbi.nlm.nih.gov/pubmed/32722104
http://dx.doi.org/10.3390/biom10081100
work_keys_str_mv AT sahekitakeyori agc2citrindeficiencyfromrecognitionofthediseasetillconstructionoftherapeuticprocedures
AT moriyamamitsuaki agc2citrindeficiencyfromrecognitionofthediseasetillconstructionoftherapeuticprocedures
AT funahashiaki agc2citrindeficiencyfromrecognitionofthediseasetillconstructionoftherapeuticprocedures
AT kurodaeishi agc2citrindeficiencyfromrecognitionofthediseasetillconstructionoftherapeuticprocedures